# Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

> **NCT03004833** · PHASE2 · COMPLETED · sponsor: **University of Cologne** · enrollment: 110 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Adriamycin
- **DRUG:** Vinblastine
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT03004833
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-21
- **Primary completion:** 2022-08-22
- **Final completion:** 2022-08-22
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004833, "Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03004833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*